BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dong Y, Zhang Y, Feng Y, An W. The protective roles of augmenter of liver regeneration in hepatocytes in the non-alcoholic fatty liver disease. Front Pharmacol 2022;13:928606. [DOI: 10.3389/fphar.2022.928606] [Reference Citation Analysis]
2 Yang K, Chen J, Zhang T, Yuan X, Ge A, Wang S, Xu H, Zeng L, Ge J. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front Immunol 2022;13:949746. [DOI: 10.3389/fimmu.2022.949746] [Reference Citation Analysis]
3 Shao L, Shi J, Fan X. Tiny but mighty: Possible roles of bacterial extracellular vesicles in gut‐liver crosstalk for non‐alcoholic fatty liver disease. Clinical and Translational Dis 2022;2. [DOI: 10.1002/ctd2.115] [Reference Citation Analysis]
4 Lombardi R, Piciotti R, Dongiovanni P, Meroni M, Fargion S, Fracanzani AL. PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. Int J Mol Sci 2022;23:2707. [PMID: 35269846 DOI: 10.3390/ijms23052707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]